Prevention of Venous Thromboembolism Among Hospitalized Medical Patients

Abstract

HomeCirculationVol. 111, No. 1Prevention of Venous Thromboembolism Among Hospitalized Medical Patients Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBPrevention of Venous Thromboembolism Among Hospitalized Medical Patients Samuel Z. Goldhaber, MD and Alexander G.G. Turpie, MD Samuel Z. GoldhaberSamuel Z. Goldhaber From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (S.Z.G.), and the Department of Medicine, McMaster University, HHS-General Hospital, Hamilton, Ontario, Canada (A.G.G.T.). Search for more papers by this author and Alexander G.G. TurpieAlexander G.G. Turpie From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (S.Z.G.), and the Department of Medicine, McMaster University, HHS-General Hospital, Hamilton, Ontario, Canada (A.G.G.T.). Search for more papers by this author Originally published4 Jan 2005https://doi.org/10.1161/01.CIR.0000150393.51958.54Circulation. 2005;111:e1–e3Case presentation: A 79-year-old woman was noted by staff at her skilled nursing facility to have increasing shortness of breath during the previous 24 to 48 hours. She had been receiving daily physical therapy, occupational therapy, and 6 prescription medications to manage underlying congestive heart failure with preserved systolic function. The woman was hospitalized. After being transferred to the emergency department, she underwent further workup, which showed no pulmonary embolism on chest CT scan. The chest x-ray, however, revealed a new right lobar infiltrate and consolidation, which are consistent with pneumonia. On examination, she was alert, with a respiratory rate of 24 per minute, heart rate of 96 bpm, blood pressure of 154/76 mm Hg, temperature of 38°C, distended neck veins, right lower lung zone posterior musical rales, regular heart rhythm, normal S1, single S2, and grade II/VI systolic murmur at the left lower sternal border. The diagnosis of pneumonia was made, and levofloxacin was initiated in the emergency department. Specific evaluation of her medical regimen, including furosemide, potassium chloride, metoprolol, candesartan, simvastatin, and baby aspirin, was recommended.The ProblemPrevention of venous thromboembolism has been neglected in hospitalized patients with medical illnesses such as congestive heart failure, chronic lung disease, cancer, and infectious diseases. In the Medical Intensive Care Unit (MICU) at Brigham and Women’s Hospital, we found a combination of omitted and ineffective prophylaxis. When we performed venous ultrasound examinations on 100 patients admitted to the MICU with an anticipated stay of >48 hours, we detected deep vein thrombosis (DVT) in 33%.1 Almost 50% of the patients with DVT had proximal leg DVT. The remainder had calf DVT or upper-extremity DVT.In a subsequent audit of 384 patients who developed in-hospital DVT or pulmonary embolism after admission to Brigham and Women’s Hospital, 52% had received ineffective prophylaxis, and 48% had received no prophylaxis whatsoever.2 Of the 183 patients who received no prophylaxis, 110 (60%) were medical patients and 73 (40%) were surgical patients. Overall, pulmonary embolism caused or was a major contributor to 13 (3.4%) deaths in this cohort of 384 patients. Of the 13 deaths from pulmonary embolism, 11 patients were on the medical service and 2 were on the thoracic surgical service.The problem of inadequate and omitted prophylaxis in hospitalized patients with medical illness appears to be widespread throughout North America. In a prospective registry of 5451 patients with ultrasound-confirmed DVT conducted at 183 US hospitals, 3894 (71%) had not received prophylaxis before they developed DVT.3 Of these 3894 patients, 2295 (59%) were nonsurgical. The most common medical comorbidities were hypertension (50%), immobility (34%), cancer (32%), previous DVT (22%), and neurological disease (22%).It remains frustrating that effective and safe prophylaxis measures exist but are not universally implemented in hospitalized medical patients. The majority of DVT that develops in hospitalized patients occurs in medical rather than in surgical or trauma patients, who benefit from higher rates of effective preventive measures.Straightforward SolutionsMedical patients have available to them mechanical, pharmacological, and combined mechanical-plus-pharmacological strategies that can markedly reduce the frequency of DVT or pulmonary embolism with a low rate of complications.Mechanical ProphylaxisMechanical measures include graduated compression stockings and intermittent pneumatic compression (IPC) devices. Both graduated compression stockings and IPC devices increase venous blood flow and decrease venous stasis. In addition, IPC devices stimulate endogenous fibrinolytic activity4,5 by causing gentle trauma to the vascular endothelial cells of the lower leg and by altering rheological characteristics and perfusion pressure.Pharmacological ProphylaxisThe greatest advances in prophylaxis of medical patients have emerged from 3 large, rigorously conducted randomized double-blind placebo-controlled trials (Table): (1) MEDENOX (Prophylaxis in Medical Patients with Enoxaparin),6 (2) PREVENT (Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients Trial),7 and (3) ARTEMIS (Arixtra for ThromboEmbolism Prevention in a Medical Indications Study).8 The 3 trials share an important common theme: once-daily fixed low doses of 2 low-molecular-weight heparins (enoxaparin 40 mg in MEDENOX [enoxaparin 20 mg was no more effective than was placebo] and dalteparin 5000 U in PREVENT) and a once-daily fixed low dose of pentasaccharide (fondaparinux 2.5 mg in ARTEMIS) are effective and safe. All 3 pharmacological regimens approximately halved the DVT rate as compared with placebo, without increasing the major bleeding complication rate. Large-Scale Randomized Placebo-Controlled Trials of Venous Thromboembolism Prophylaxis in Hospitalized Medical PatientsMEDENOXPREVENTARTEMISVTE indicates venous thromboembolism; SCD, sudden cardiac death.No. randomized11023706849DrugEnoxaparinDalteparinFondaparinuxDVT diagnosisVenogramUltrasoundVenogramPrimary end pointVTEVTE, SCDVTEFollow-up3 mo90 d32 dReduction primary end point, %634549Major bleeding (drug), %1.70.50.2Major bleeding (placebo), %1.10.20.2These 3 trials have demonstrated that pharmacological prophylaxis should be a “default admission order” for most medical patients who are hospitalized for >1 or 2 days. In the MEDENOX trial, independent risk factors that predicted the development of venous thromboembolism included age >75 years, cancer, previous venous thromboembolism, acute infectious disease, and chronic respiratory disease.9 In the ARTEMIS trial,8 fondaparinux showed a trend toward reducing overall mortality from 6.0% in the placebo group to 3.3% in the fondaparinux group. The weight of evidence now favors pharmacological prophylaxis of medical patients at risk and precludes further placebo-controlled randomized trials in this patient population.Before the development of low-molecular-weight heparins, “mini-dose” unfractionated heparin, 5000 U 3 times daily, was the standard pharmacological preventive regimen for medical patients. In a multicenter European trial (THE-PRINCE, The Thromboembolism-Prevention in Cardiac or Respiratory Disease with Enoxaparin), 665 patients were enrolled in 64 German hospitals.10 Half had heart failure and half had severe respiratory disease. In THE-PRINCE study, which was designed as an equivalence trial, patients were randomized to receive open-label heparin 5000 U 3 times daily versus enoxaparin 40 mg once daily; DVT was diagnosed with contrast venography. There was no difference in efficacy or safety with these 2 prophylactic strategies.AspirinIn a meta-analysis of trials of antiplatelet therapy, the risk of symptomatic pulmonary embolism was reduced with antiplatelet therapy from 0.61% to 0.46%.11 Nevertheless, antiplatelet therapy is not the standard of care for the prevention of venous thromboembolism in medical patients. Aspirin is warranted, however, for the prevention of heart attack and stroke.Implementing Contemporary Guidelines for ProphylaxisDespite multiple educational initiatives for healthcare providers, venous thromboembolism prophylaxis remains underused.12 Often, ineffective preventive regimens are prescribed. Some clinicians continue to perceive pharmacological prophylaxis as excessively risky because of the possibility of bleeding complications. Others find established guidelines to be too cumbersome for practical everyday use. A minority believe that small asymptomatic DVT is simply not worth the effort to prevent because these tiny thrombi cannot directly cause clinically significant pulmonary embolism.Information technology should help to improve the safety of patients at risk for DVT and pulmonary embolism.13 Computer technology will allow the identification of patients at high risk for venous thromboembolism. Future programming may permit electronic alerts to the physicians responsible for high-risk patients and may suggest appropriate prophylaxis modalities. So far, however, computer reminder systems have demonstrated only the ability to increase the frequency of prophylaxis orders14 without causing a decline in the rate of DVT or pulmonary embolism.In the future, prompt identification of hospitalized medical patients at risk of venous thromboembolism will facilitate the institution of mechanical and pharmacological prophylaxis modalities. The foundation of preventive strategies should be the completed large pharmacological trials (Table), as well as consensus guidelines for prophylaxis.15The cardiovascular specialist will focus on the cause and immediate management of congestive heart failure in people like the 79-year-old woman presented in our case study. She appears to have diastolic dysfunction, underlying systemic arterial hypertension, and a new pneumonia. The cardiologist will make sure that left ventricular function is still well preserved and will work with the referring physician to optimize heart rate and blood pressure control. With 7 active medication orders (including the antibiotic), it would be easy to overlook DVT prevention, although this patient is in a high-risk group for developing DVT. In the absence of overt bleeding, she will benefit from an eighth medication: once-daily prophylactic injections of 40 mg enoxaparin or 5000 U daily dalteparin. This incremental strategy should decrease her risk of developing DVT, with no appreciable increase in major bleeding, by 50%.FootnotesCorrespondence to Samuel Z. Goldhaber, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail [email protected] References 1 Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995; 274: 335–337.CrossrefMedlineGoogle Scholar2 Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women’s Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 2000; 118: 1680–1684.CrossrefMedlineGoogle Scholar3 Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004; 93: 259–262.CrossrefMedlineGoogle Scholar4 Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, Comerota AJ Jr, Schlappy D, Rao AK. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 1997; 226: 306–314.CrossrefMedlineGoogle Scholar5 Kessler CM, Hirsch DR, Jacobs H, MacDougall R, Goldhaber SZ. Intermittent pneumatic compression in chronic venous insufficiency favorably affects fibrinolytic potential and platelet activation. Blood Coagul Fibrinolysis. 1996; 7: 437–446.CrossrefMedlineGoogle Scholar6 Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793–800.CrossrefMedlineGoogle Scholar7 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110: 874–879.LinkGoogle Scholar8 Cohen AT, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Davidson BL, Cariou RG, Lensing AWA, Egberts JFM. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost. 2003; 1 (suppl 1): P2046. Abstract.CrossrefGoogle Scholar9 Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004; 164: 963–968.CrossrefMedlineGoogle Scholar10 Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003; 145: 614–621.CrossrefMedlineGoogle Scholar11 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71–86.CrossrefMedlineGoogle Scholar12 Kakkar AK, Davidson BL, Haas SK; The Investigators Against Thromboembolism (INATE) Core Group. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost. 2004; 2: 221–227.CrossrefMedlineGoogle Scholar13 Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003; 348: 2526–2534.CrossrefMedlineGoogle Scholar14 Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001; 345: 965–970.CrossrefMedlineGoogle Scholar15 Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism. Chest. 2004; 126: 338S–400S.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Belcaro G, Corsi M, Agus G, Cesarone M, Cornelli U, Cotellese R, Feragalli B and Hu S Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study, Minerva Medica, 10.23736/S0026-4806.20.06688-4, 111:4 Agus G and Bavera P COVID-19: the rediscovery of heparin?, Acta Phlebologica, 10.23736/S1593-232X.20.00467-1, 21:1-2 Baumann S, Becher T, Giannakopoulos K, Jabbour C, Fastner C, El-Battrawy I, Ansari U, Lossnitzer D, Behnes M, Alonso A, Kirschning T, Dissmann R, Kueck O, Stern D, Michels G, Borggrefe M and Akin I (2017) Bettseitige Implantation eines neuen passageren V.-cava-inferior-FiltersBedside implantation of a new temporary vena cava inferior filter, Medizinische Klinik - Intensivmedizin und Notfallmedizin, 10.1007/s00063-017-0294-9, 113:3, (184-191), Online publication date: 1-Apr-2018. Boyd E, Crespo A, Hutzler L, Konda S and Egol K (2018) Interfacility Transfer Is a Risk Factor for Venous Thromboembolism in Lower Extremity Fracture Patients, Journal of Orthopaedic Trauma, 10.1097/BOT.0000000000001312, 32:12, (635-639), Online publication date: 1-Dec-2018. Minges K, Bikdeli B, Wang Y, Attaran R and Krumholz H (2018) National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries, The American Journal of Medicine, 10.1016/j.amjmed.2018.04.033, 131:10, (1200-1208), Online publication date: 1-Oct-2018. Gerotziafas G, Papageorgiou L, Salta S, Nikolopoulou K and Elalamy I (2018) Updated clinical models for VTE prediction in hospitalized medical patients, Thrombosis Research, 10.1016/j.thromres.2018.02.004, 164, (S62-S69), Online publication date: 1-Apr-2018. Tatara A, Ruegger M, Adeola M and Putney D (2017) Time to Occurrence Based on Risk Stratification of Hospital-Acquired Venous Thromboembolism: A Retrospective Observational Cohort Study, Journal of Pharmacy Practice, 10.1177/0897190017735423, 31:6, (651-657), Online publication date: 1-Dec-2018. Baumann S, Becher T, Giannakopoulos K, Jabbour C, Rutsch M, Fastner C, El-Battrawy I, Ansari U, Lossnitzer D, Behnes M, Alonso A, Kirschning T, Michels G, Stern D, Dissmann R, Kueck O, Taccone F, Waldmann C, Bunker N, Postiglione M, Borggrefe M and Akin I (2018) Bedside implantation of a new temporary vena cava inferior filter - Safety and efficacy results of the European ANGEL-Registry, Journal of Critical Care, 10.1016/j.jcrc.2017.10.009, 44, (39-44), Online publication date: 1-Apr-2018. Rose P (2017) Risk Factors for Venous Thromboembolism Handbook of Venous Thromboembolism, 10.1002/9781119095606.ch1, (1-12) Minges K, Bikdeli B, Wang Y, Kim N, Curtis J, Desai M and Krumholz H (2015) National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65 Years in the United States (1999 to 2010), The American Journal of Cardiology, 10.1016/j.amjcard.2015.07.068, 116:9, (1436-1442), Online publication date: 1-Nov-2015. Lee J, Grochow D, Drake D, Johnson L, Reed P and van Servellen G (2014) Evaluation of hospital nurses' perceived knowledge and practices of venous thromboembolism assessment and prevention, Journal of Vascular Nursing, 10.1016/j.jvn.2013.06.001, 32:1, (18-24), Online publication date: 1-Mar-2014. Agharezaei Z, Bahaadinbeigy K, Tofighi S, Agharezaei L and Nemati A (2014) Attitude of Iranian physicians and nurses toward a clinical decision support system for pulmonary embolism and deep vein thrombosis, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2014.03.007, 115:2, (95-101), Online publication date: 1-Jul-2014. Kakkar A and Rushton-Smith S (2013) Incidence of Venous Thromboembolism in Orthopedic Surgery Thromboembolism in Orthopedic Surgery, 10.1007/978-1-4471-4336-9_2, (11-17), . Nicolaides A, Fareed J, Kakkar A, Comerota A, Goldhaber S, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini J, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen M, Lowe G, Markel A, Prandoni P, Raskob G, Spyropoulos A, Turpie A, Walenga J and Warwick D (2013) Medical Patients, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029612474840i, 19:2, (163-171), Online publication date: 1-Apr-2013. Parikh K, Oh D, Sittipunt C, Kalim H, Ullah S and Aggarwal S (2012) Venous thromboembolism prophylaxis in medical ICU patients in Asia (VOICE Asia): A multicenter, observational, cross-sectional study, Thrombosis Research, 10.1016/j.thromres.2012.01.012, 129:4, (e152-e158), Online publication date: 1-Apr-2012. Hogg K, Thomas D, Mackway-Jones K, Lecky F and Cruickshank K (2011) Diagnosing pulmonary embolism: a comparison of clinical probability scores, British Journal of Haematology, 10.1111/j.1365-2141.2011.08575.x, 153:2, (253-258), Online publication date: 1-Apr-2011. Baser O, Supina D, Sengupta N, Wang L and Kwong L (2010) Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery, Current Medical Research and Opinion, 10.1185/03007995.2010.545940, 27:2, (423-429), Online publication date: 1-Feb-2011. Kakkar A and Rushton-Smith S (2011) Venous Thromboembolism Pharmacologic Prophylaxis After Major Surgery—Are We Doing Well or Not Well Enough?, Annals of Surgery, 10.1097/SLA.0b013e318208f427, 253:2, (221-222), Online publication date: 1-Feb-2011. Slaughter T (2010) Coagulation Miller's Anesthesia, 10.1016/B978-0-443-06959-8.00056-X, (1767-1779), . Herbers J and Zarter S (2010) Prevention of venous thromboembolism in Department of Veterans Affairs hospitals, Journal of Hospital Medicine, 10.1002/jhm.597, 5:1, (E21-E25), Online publication date: 1-Jan-2010. (2010) Tromboprofilaxia primária, Jornal Brasileiro de Pneumologia, 10.1590/S1806-37132010001300015, 36:suppl 1, (43-48), Online publication date: 1-Mar-2010. Páramo J and Lecumberri R (2009) Enfermedad tromboembólica venosa: una llamada urgente a la acción, Medicina Clínica, 10.1016/j.medcli.2009.02.049, 133:14, (547-551), Online publication date: 1-Oct-2009. Burlingame B (2009) Prophylactic treatment for DVT, Nursing, 10.1097/01.MIN.0000348074.09561.79, 39:3, (5-13), Online publication date: 1-Mar-2009. Andrade E, Bindá F, Silva Â, Costa T, Fernandes M and Fernandes M (2009) Fatores de risco e profilaxia para tromboembolismo venoso em hospitais da cidade de Manaus, Jornal Brasileiro de Pneumologia, 10.1590/S1806-37132009000200003, 35:2, (114-121), Online publication date: 1-Feb-2009. Friberg H and Nielsen N (2009) Hypothermia after Cardiac Arrest: Lessons Learned from National Registries, Journal of Neurotrauma, 10.1089/neu.2008.0637, 26:3, (365-369), Online publication date: 1-Mar-2009. Park B, Messina L, Dargon P, Huang W, Ciocca R and Anderson F (2009) Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States, Chest, 10.1378/chest.08-2258, 136:4, (983-990), Online publication date: 1-Oct-2009. GOLDHABER S (2007) Preventing pulmonary embolism and deep vein thrombosis: a ?call to action? for vascular medicine specialists, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2007.02651.x, 5:8, (1607-1609), Online publication date: 1-Aug-2007. Piazza G, Seddighzadeh A and Goldhaber S (2007) Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis, Chest, 10.1378/chest.07-0430, 132:2, (554-561), Online publication date: 1-Aug-2007. Goldhaber S (2007) Venous Disease Cardiovascular Medicine, 10.1007/978-1-84628-715-2_82, (1705-1716), . (2007) Venous Thromboembolism The Most Common Inpatient Problems in Internal Medicine, 10.1016/B978-141603203-8.10010-5, (199-221), . Henke P, Ferguson E, Varma M, Deatrick K, Wakefield G and Woodrum D (2007) Proximate versus nonproximate risk factor associated primary deep venous thrombosis: Clinical spectrum and outcomes, Journal of Vascular Surgery, 10.1016/j.jvs.2007.01.042, 45:5, (998-1007), Online publication date: 1-May-2007. Henke P, Froehlich J, Upchurch G and Wakefield T (2007) Impacts négatifs significatifs de la maladie veineuse thromboembolique sur les résultats des interventions cardiovasculaires, Annales de Chirurgie Vasculaire, 10.1016/j.acvfr.2007.12.002, 21:5, (163-169), Online publication date: 1-Sep-2007. Henke P, Froehlich J, Upchurch G and Wakefield T (2007) The Significant Negative Impact of In-Hospital Venous Thromboembolism after Cardiovascular Procedures, Annals of Vascular Surgery, 10.1016/j.avsg.2007.03.027, 21:5, (545-550), Online publication date: 1-Sep-2007. Urbankova J, Quiroz R and Goldhaber S (2016) Intermittent pneumatic compression and deep vein thrombosis prevention in postoperative patients, Phlebology: The Journal of Venous Disease, 10.1258/026835506778243031, 21:1_suppl, (19-22), Online publication date: 1-Jun-2006. Kehl-Pruett W (2006) Deep Vein Thrombosis in Hospitalized Patients, Dimensions of Critical Care Nursing, 10.1097/00003465-200603000-00001, 25:2, (53-59), Online publication date: 1-Mar-2006. ERIKSSON B, BORRIS L, DAHL O, HAAS S, HUISMAN M, KAKKAR A, MISSELWITZ F and KÄLEBO P (2005) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2005.01657.x, 4:1, (121-128), Online publication date: 1-Jan-2006. KHAN M (2006) Deep Vein Thrombosis Encyclopedia of Heart Diseases, 10.1016/B978-012406061-6/50049-7, (287-290), . Tilleul P, Tredan G, Austruy G, Maury E, Offenstadt G and Guidet B (2006) Prophylactic low-molecular-weight heparin: Prescription practice in an intensive care unit, Journal of Critical Care, 10.1016/j.jcrc.2005.12.013, 21:2, (173-178), Online publication date: 1-Jun-2006. Henke P (2005) Improving quality of care in vascular surgery: the tools are available now, The American Journal of Surgery, 10.1016/j.amjsurg.2005.05.036, 190:2, (333-337), Online publication date: 1-Aug-2005. Singh V, Muthusamy N, Ikwuazom C, Sicat C, Schwarzkopf R and Rozell J (2021) Postoperative venous thromboembolism event increases risk of readmissions and reoperation following total joint arthroplasty: a propensity-matched cohort study, European Journal of Orthopaedic Surgery & Traumatology, 10.1007/s00590-021-03071-4 January 4, 2005Vol 111, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000150393.51958.54PMID: 15630031 Originally publishedJanuary 4, 2005 PDF download Advertisement SubjectsAnticoagulantsEpidemiology